TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04903093
Drug: Abrocitinib Suspension F1
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
Study: NCT04903093
Drug: Abrocitinib Suspension F2
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
Study: NCT04903093
Drug: Abrocitinib Suspension F3
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
Study: NCT04903093
Drug: Abrocitinib Suspension F4
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
Study: NCT04903093
Drug: Abrocitinib Suspension F5
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
Study: NCT04903093
Drug: Abrocitinib Suspension F6
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
Study: NCT04903093
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
Study: NCT04290897
Drug: Anhydrous Enol-oxaloacetate
Normalized name: Anhydrous enol-oxaloacetate
DrugBank: Oxaloacetic acid (DB16921)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05490472
Drug: JAB-2485 (Aurora A inhibitor)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06439992
Drug: 18F-Fluselenamyl
Normalized name: (18F)-Fluoride
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.
Study: NCT05609240
Drug: Cefuroxime
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm/group description
Study: NCT06535893
Drug: TN
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
Study: NCT06535893
Drug: TN-1
Normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
Study: NCT05461794
Drug: Sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT05461794
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously
Study: NCT05461794
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered intravenously
Study: NCT05461794
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered intravenously
Study: NCT05863910
Drug: Medical Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any cannabis product that is available to participants through the Medical Cannabis Access Program is eligible to be included in this study.
Study: NCT05105061
Drug: Ketamine (Ketalar)
Normalized name: ketamine Injectable Solution [Ketalar]
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg of body weight
Study: NCT04953221
Drug: YJ001
Normalized name: Yttrium (90Y) ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Skin spray
Study: NCT05663307
Drug: Ginkgo diterpene lactone meglumine injection
Normalized name: citronellene lactone
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
Study: NCT06070948
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral; Tablet
Study: NCT04652765
Drug: Camostat Mesilate
Normalized name: Camostat mesilate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat 600mg by mouth four times a day, for a total of 7 days
Study: NCT04652765
Drug: Bicalutamide 150 mg
Normalized name: bicalutamide 150 MG
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 150mg by mouth once daily, for a total of 7 days
Study: NCT05663307
Drug: Ginkgo diterpene lactone meglumine injection simulation
Normalized name: citronellene lactone
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
Study: NCT06675188
Drug: PF-07275315
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07275315 solution for injection (single use only)
Study: NCT05663307
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: plus aspirin at a dose of 100 mg per day for 90 days.
Study: NCT06674941
Drug: Teprotumumab
Normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as an SC injection.
Study: NCT06674343
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib 160mg, once daily, orally. Other Names: AST2818
Study: NCT06447727
Drug: SIRT with Yttrium-90 Microspheres
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection
Study: NCT06447727
Drug: FOLFIRI and Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FOLFIRI and Bevacizumab
Study: NCT06180590
Drug: Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
Normalized name: sofosbuvir / velpatasvir / voxilaprevir Oral Tablet [Vosevi]
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evaluate the efficacy of Vosevi in DAAs-experienced patients
Study: NCT06673784
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Most one natural and not effects on study
Study: NCT06675500
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Magnesium sulphate followed by oral tablets of Magnesium sulphate
Study: NCT06675851
Drug: Cipralex (escitalopram)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
Study: NCT05965479
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
Study: NCT06685991
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.
Study: NCT06691243
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.
Study: NCT06688175
Drug: IMRT combined with lobaplatin-based concurrent chemotherapy
Normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT combined with two cycles of lobaplatin-based concurrent chemotherapy
Study: NCT06504966
Drug: MAB-22
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
DrugBank: AB-22 (DB18296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of 60 mg
Study: NCT05365880
Drug: Liquid Lidocaine
Normalized name: lidocaine Medicated Liquid Soap
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational treatment is 2 mL of aqueous 2% lidocaine.
Study: NCT05690204
Drug: SAP-001
Normalized name: HURA CREPITANS SAP
DrugBank: AP-001 (DB18511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test the efficacy and safety of SAP-001 versus placebo
Study: NCT06089317
Drug: TCM ultrasonic atomization treatment with herbal Compound Decoction (CD)
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the CD group is TCM compound decoction.~The prescription of atomization solution in the CD group contains Honeysuckle flower (金銀花) 5g, Chrysanthemum flower (菊花) 5g, Pale betterflybush flower (密蒙花) 5g, Mild mint herb (薄荷) 5g, Barbary wolfberry fruit (枸杞子) 10g, and Ophiopogon japonicus (麥冬) 5g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.
Study: NCT06089317
Drug: Artificial Tears (AT)
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
Study: NCT05381753
Drug: Avapritinib
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.
Study: NCT04020263
Drug: Levosimendan 2.5 MG/ML Injectable Solution
Normalized name: levosimendan 2.5 MG/ML Injectable Solution
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
Study: NCT04722809
Drug: Botulinum toxin injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
Study: NCT04781972
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of 10 mg or 15 mg
Study: NCT06425341
Drug: HRS-5635 Injection
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5635 Injection low dose administered by subcutaneous injection
Study: NCT06425341
Drug: HRS-5635 Injection
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5635 Injection medium dose administered by subcutaneous injection
Study: NCT06425341
Drug: HRS-5635 Injection
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5635 Injection high dose administered by subcutaneous injection
Study: NCT06425341
Drug: HRS-5635 Injection
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5635 Injection lowest dose administered by subcutaneous injection
Study: NCT06244823
Drug: Fremanezumab Prefilled Syringe
Normalized name: fremanezumab Prefilled Syringe
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.
Study: NCT05294146
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.~Blood samples will be taken at Day 28 (+/- 2 days), Day 29 (Day 28 +1) and after 4 months of treatment to assess the pharmacokinetics of CFZ, both with the loading dose and the standard dose. In addition, the safety/tolerability of CFZ will monitored.
Study: NCT05016973
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.0mg/kg, Intravenous drip on days 1 every 21 days
Study: NCT05016973
Drug: Triplizumab
Normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg, Intravenous drip on days 1 every 21 days
Study: NCT02772120
Drug: Vaginal progesterone gel (Crinone® 8%)
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
Study: NCT02772120
Drug: Intramuscular Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
Study: NCT06268093
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 50 - 200 mg once at nightime
Study: NCT05264077
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
Study: NCT05631886
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous abraxane 125 mg/m\^2/day on day-5.
Study: NCT05631886
Drug: anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anti-PD-1 antibody 200 mg/day.
Study: NCT05631886
Drug: Anti-CTLA4 Monoclonal Antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous anti-CTLA4 antibody 1 mg/kg/day
Study: NCT06318546
Drug: Dexmedetomidine Injection [Precedex],,,
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive 0.5ml (10 µg) Dexmedetomidine as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
Study: NCT04642430
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Refer to Apixaban group
Study: NCT04642430
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Refer to Rivaroxaban group
Study: NCT05700617
Drug: 1:1 Randomization to receive milrinone or dobutamine
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized to receive either inotropic agent: milrinone or dobutamine
Study: NCT05700617
Drug: 1:1 Randomization to receive dobutamine or milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized to receive either inotropic agent: milrinone or dobutamine
Study: NCT05849246
Drug: Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®
Study: NCT05849246
Drug: Sintilimab+Carboplatin or Cisplatin+Pemetrexed
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Study: NCT05849246
Drug: Tusamitamab ravtansine+Sintilimab
Normalized name: mirvetuximab soravtansine
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®
Study: NCT04724252
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.
Study: NCT04287829
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion
Study: NCT04287829
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsule
Study: NCT04876391
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab
Study: NCT06332755
Drug: LB-LR1109
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT05754996
Drug: Nifuroxazide
Normalized name: nifuroxazide
DrugBank: Nifuroxazide (DB13855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifuroxazide dosing : 200 mg capsule four times daily
Study: NCT05754996
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools
Study: NCT05754996
Drug: Rifaximin 550Mg Tab
Normalized name: RIFAXIMIN 550MG TAB
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 550 MG twice daily
Study: NCT05430919
Drug: REGN5713
Normalized name: Immunoglobulin G4 [224-proline], anti-(Betula alleghaniensis allergen Bet v 1) (human monoclonal REGN5713 γ4-chain), disulfide with human monoclonal REGN5713 κ-chain, dimer
DrugBank: Bremzalerbart (DB19417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT05503147
Drug: Sativex
Normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
Study: NCT06494644
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.
Study: NCT06494644
Drug: AZD6793+ Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
Study: NCT05888233
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then increased to 600mg/daily for an additional 4 weeks.
Study: NCT04755387
Drug: Ticagrelor 90mg
Normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard strategy initially receive ticagrelor 90mg twice daily for 12 months.